Therapeutic effect of a novel oxazolidinone, DA-7867, in BALB/c mice infected with Nocardia brasiliensis

PLoS Neglected Tropical Diseases

Volumn 2, Issue 9, 2008, Pages

  Vera Cabrera, Lucio ^a   Daw Garza, Alejandra ^a   Said Fernández, Salvador ^b   Lozano Garza, Hector Gerardo ^b   de Torres, Noemi Waksman ^c   Rocha, Norma Cavazos ^c   Ocampo Candiani, Jorge ^a   Choi, Sung Hak ^d,e   Welsh, Oliverio ^a  

^a HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^c UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN   (Mexico)

^d Dong A Pharmaceutical Company   (South Korea)

^e Sungkyunkwan University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

DA 7867; LINEZOLID; OXAZOLIDINONE DERIVATIVE; SODIUM CHLORIDE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; DA-7867;

ACTINOMYCETOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIUM CULTURE; BAGG ALBINO MOUSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VIVO STUDY; MOUSE; NOCARDIA BRASILIENSIS; NOCARDIOSIS; NONHUMAN; OPTIMAL DRUG DOSE; ACTINOMYCETALES INFECTION; AFRICA; ANIMAL; BLOOD; HUMAN; INDIA;

ACTINOMYCETALES INFECTIONS; AFRICA; ANIMALS; ANTI-INFECTIVE AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; INDIA; MICE; MICE, INBRED BALB C; NOCARDIA INFECTIONS; OXAZOLIDINONES;

EID: 56149095272     PISSN: None     EISSN: None     Source Type: Journal    
DOI: 10.1371/journal.pntd.0000289     Document Type: Article

References (16)

1. Lopez Martinez R, Mendez Tovar LJ, Lavalle P, Welsh O, Saul A, Macotela Ruiz E (1992) [Epidemiology of mycetoma in Mexico: study of 2105 cases]. Gac Med Mex 128: 477-481.
2. Welsh O, Vera-Cabrera L, Salinas-Carmona MC (2007) Mycetoma. Clin Dermatol 25: 195-202.
3. Welsh O, Vera-Cabrera L (2003) Abstr. 15th Cong. Int. Soc. Human and Anim. Mycol., abstr. 354, San Antonio, Texas.
4. Bozdogan B, Appelbaum PC (2004) Oxazolidinones: activity, mode of action, and mechanism of resistance. Int J Antimicrob Agents 23: 113-119.
5. Vera-Cabrera L, Gonzalez E, Choi SH, Welsh O (2004) In vitro activities of new antimicrobials against Nocardia brasiliensis. Antimicrob Agents Chemother 48: 602-604.
6. Vera-Cabrera L, Ochoa-Felix EY, Gonzalez G, Tijerina R, Choi SH, Welsh O (2004) In vitro activities of new quinolones and oxazolidinones against Actinomadura madurae. Antimicrob Agents Chemother 48: 1037-1039.
7. Vera-Cabrera L, Castro-Garza J, Rendon A, Ocampo-Candiani J, Welsh O, Choi SH, Blackwood K, Molina-Torres C (2005) In vitro susceptibility of Mycobacterium tuberculosis clinical isolates to garenoxacin and DA-7867. Antimicrob Agents Chemother 49: 4351-4353.
8. Gomez-Flores A, Welsh O, Said-Fernandez S, Lozano-Garza G, Tavarez-Alejandro RE, Vera-Cabrera L (2004) In vitro and in vivo activities of antimicrobials against Nocardia brasiliensis. Antimicrob Agents Chemother 48: 832-837.
9. Moylett EH, Pacheco SE, Brown-Elliott BA, Perry TR, Buescher ES, Birmingham MC, Schentag JJ, Gimbel JF, Apodaca A, Schwartz MA, Rakita RM, Wallace RJ Jr (2003) Clinical experience with linezolid for the treatment of nocardia infection. Clin Infect Dis 36: 313-318.
10. Park IN, Hong SB, Oh YM, Kim MN, Lim CM, Lee SD, Koh Y, Kim WS, Kim DS, Kim WD, Shim TS (2006) Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis. J Antimicrob Chemother 58: 701-704.
11. Espinoza-González NA, Welsh O, de Torres NW, Cavazos-Rocha N, Ocampo-Candiani J, Said-Fernandez S, Lozano-Garza G, Choi SH, Vera-Cabrera L (2008) Efficacy of DA-7218, a new oxazolidinone prodrug, in the treatment of experimental actinomycetoma produced by Nocardia brasiliensis. Molecules 13: 31-40.
12. Daw-Garza A, Welsh O, Said-Fernández S, Lozano-Garza HG, Waksman De Torres N, Cavazos-Rocha N, Ocampo-Candiani J, Vera-Cabrera L (2008) In vivo therapeutic effect of gatifloxacin on BALB/c mice infected with Nocardia brasiliensis. Antimicrob Agents Chemother 52: 1549-1550.
13. Cavazos-Rocha N, Vera-Cabrera L, Welsh-Lozano O, Waksman-de-Torres N, de la Luz Salazar-Cavazos M (2007) Simultaneous determination and validation of antimicrobials in plasma and tissue of actinomycetoma by high-performance liquid chromatography with diode array and fluorescence detection. J Pharm Biomed Anal 43: 1775-1781.
14. Bae SK, Chung WS, Kim EJ, Rhee JK, Kwon JW, Kim WB, Lee MG (2004) Pharmacokinetics of DA-7867, a new oxazolidinone, after intravenous or oral administration to rats: intestinal first-pass effect. Antimicrob Agents Chemother 48: 659-662.
15. Park-Wyllie LY, Juurlink DN, Kopp A, Shah BR, Stukel TA, Stumpo C, Dresser L, Low DE, Mamdani MM (2006) Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 354: 1352-1361.
16. Rustomjee R, Lienhardt C, Kanyok T, Davies GR, Levin J, Mthiyane T, Reddy C, Sturm AW, Sirgel FA, Allen J, Coleman DJ, Fourie B, Mitchison DA, Gatifloxacin for TB (OFLOTUB) study team (2008) A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 12: 128-138.